What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2373.png

 

Arthrofast 150mg modified release tablets

 

Indication

 

Arthrofast® 150mg – Symptomatic treatment of pain and inflammation in case of:1

  • Chronic joint inflammation, especially rheumatoid arthritis (chronic polyarthritis) 

 

 

Dosage

 

  • Adults are given 1 modified-release tablet (equivalent to 150 mg diclofenac sodium).1

  • The recommended adult diclofenac dose range is between 50 and 150 mg diclofenac sodium per day and should not be exceeded.1

gg 1.png

 

Efficacy

 

Group 2389.png

  • VAS: Visual analogue scale, NSAID: Non-steroidal anti-inflammatory drugs

  • Diclofenac (150 mg/day) is likely to be more efficacious in alleviating osteoarthritis (OA) or rheumatoid arthritis (RA) pain compared to other treatments at week 12.2

  • A network meta-analysis involving 146,524 patients across 176 studies evaluated the efficacy, safety, and tolerability of various treatments and found that diclofenac was more likely to be effective in relieving OA or RA pain than celecoxib (200 mg/day), naproxen (1000 mg/day), and ibuprofen (2400 mg/day), while demonstrating similar efficacy to etoricoxib (60 mg/day)2

ChatGPT Image Jun 24, 2025, 05_20_20 PM 1.png

 

Arthrofast® showed an improvement in physical functioning in 6 weeks in patients with osteoarthritis or rheumatoid arthritis.2

 

Arthrofast® (diclofenac 150 mg/day) has been shown to be more effective in improving physical functioning compared to both naproxen and placebo, based on Likert assessment, over a treatment period of six weeks.2

 

OA: Osteoarthritis, RA: Rheumatoid arthritis. 

For Arthrofast® Abbreviated prescribing information

PDF
View

References

  1. Arthrofast® 150mg. Egyptian Drug Authority approved insert leaflet, Approval date:22/01/2024

  2. Van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis research & therapy. 2015;17(1):1-8. 

Approved by Egyptian Drug Authority: HF0082OA4734/092025. Invalidation date: 01/09/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg

Ortho QR Code

HF0082OA4734/092025
01/09/2027

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting